Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Bone marrow transplantation·2026
Same author

[Do chemotherapies still have a place in the era of precision medicine?]

Bulletin du cancer·2026
Same author

[Decoding and guidelines].

Bulletin du cancer·2026

Related Experiment Video

Updated: Aug 5, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.2K

[Rare tumors: Angiosarcoma].

Nathan El-Ghazzi1, Jacques-Olivier Bay1

  • 1CHU Gabriel-Montpied, service d'oncologie médicale, Clermont-Ferrand, France; Université Clermont Auvergne, Clermont-Ferrand, France.

Bulletin Du Cancer
|March 27, 2023
PubMed
Summary

Angiosarcomas, rare soft tissue sarcomas, have poor prognosis despite treatment advances. Research is exploring new biomarkers and immunotherapies for better precision medicine in angiosarcoma patients.

Keywords:
AngiosarcomaAngiosarcomeBiologie moléculaireChemotherapyChimiothérapieImmunotherapyImmunothérapieMolecular biologySarcome des tissus mousSoft tissue sarcoma

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K

Related Experiment Videos

Last Updated: Aug 5, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K

Area of Science:

  • Oncology
  • Pathology

Context:

  • Angiosarcomas are rare soft tissue sarcomas (1-2% of cases).
  • Risk factors include radiotherapy and lymphedema, often post-breast cancer treatment.
  • Prognosis remains poor with a 5-year survival rate of 35-40%.

Purpose:

  • To review current knowledge on angiosarcoma diagnosis, treatment, and emerging research.
  • To highlight the need for improved understanding of angiosarcoma biology for targeted therapies.

Summary:

  • Optimal local treatment involves R0 surgery with adjuvant radiation.
  • Metastatic disease management includes chemotherapy (doxorubicin, paclitaxel) and metastasectomy for oligometastatic cases.
  • Emerging research focuses on novel biomarkers and immunotherapy, particularly for head and neck angiosarcomas.

Impact:

  • Advances in understanding angiosarcoma biology are crucial for developing precision medicine strategies.
  • Patient-participating studies like the angiosarcoma project are vital for rare tumor research.
  • Focus on molecular mechanisms will guide future therapeutic development and improve patient outcomes.